These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18927314)

  • 21. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
    Kummar S; Gutierrez ME; Gardner ER; Chen X; Figg WD; Zajac-Kaye M; Chen M; Steinberg SM; Muir CA; Yancey MA; Horneffer YR; Juwara L; Melillo G; Ivy SP; Merino M; Neckers L; Steeg PS; Conley BA; Giaccone G; Doroshow JH; Murgo AJ
    Eur J Cancer; 2010 Jan; 46(2):340-7. PubMed ID: 19945858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
    Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
    Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
    Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
    Fracasso PM; Williams KJ; Chen RC; Picus J; Ma CX; Ellis MJ; Tan BR; Pluard TJ; Adkins DR; Naughton MJ; Rader JS; Arquette MA; Fleshman JW; Creekmore AN; Goodner SA; Wright LP; Guo Z; Ryan CE; Tao Y; Soares EM; Cai SR; Lin L; Dancey J; Rudek MA; McLeod HL; Piwnica-Worms H
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1225-37. PubMed ID: 20694727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
    Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
    Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Goetz MP; Toft D; Reid J; Ames M; Stensgard B; Safgren S; Adjei AA; Sloan J; Atherton P; Vasile V; Salazaar S; Adjei A; Croghan G; Erlichman C
    J Clin Oncol; 2005 Feb; 23(6):1078-87. PubMed ID: 15718306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
    Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
    Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
    Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
    Hoff PM; Wolff RA; Bogaard K; Waldrum S; Abbruzzese JL
    Jpn J Clin Oncol; 2006 Feb; 36(2):100-3. PubMed ID: 16449240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
    Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
    Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
    Garcia AA; Pujari M; Jeffers S; Iqbal S; Lenz HJ; Beringer P; Louie S
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):75-82. PubMed ID: 15809878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.